NSE: ASTEC | BSE: 533138

Weak Stock

Download real time

667.10 -6.05 (-0.90%)

Near 52W Low of ₹647.50

20,209 NSE+BSE Volume

NSE 06 May, 2025 1:01 PM (IST)

1,308.3

Market Cap

Above industry Median

0.6

Beta 1Year

Very Low volatility

Astec Lifesciences Ltd. share price target and research reports

Name: Latest research reports of Astec Lifesciences Ltd. authored by ICICI Direct and published by - Trendlyne research reports.
Item: Astec Lifesciences Ltd.
Rating: 1
Author: ICICI Direct

Latest analyst research reports with target prices and PDF download for ASTEC, BSE:533138 Astec Lifesciences Ltd.

Search Inside the pdf :

Astec Lifesciences Ltd.

18 May 2023

667.10

-0.90%

Astec Lifesciences

Sell: Astec Lifesciences Ltd.

Target

ICICI Direct

Astec Lifesciences Ltd. has lost -45.86% in the last 1 Year

Astec Lifesciences Ltd.

09 Feb 2023

667.10

-0.90%

Astec Lifesciences

Sell: Astec Lifesciences Ltd.

Recommendation Target

ICICI Direct

Number of FII/FPI investors decreased from 27 to 13 in Mar 2025 qtr

Astec Lifesciences Ltd.

27 Jul 2022

667.10

-0.90%

Astec Lifesciences

Buy: Astec Lifesciences Ltd.

ICICI Direct

Astec Lifesciences Ltd. has lost -29.01% in the last 3 Months

Astec Lifesciences Ltd.

04 May 2022

667.10

-0.90%

Astec Lifesciences

Buy: Astec Lifesciences Ltd.

ICICI Direct

Astec Lifesciences Ltd. has lost -29.01% in the last 3 Months

Astec Lifesciences Ltd.

28 Oct 2021

667.10

-0.90%

Astec Lifesciences

Buy: Astec Lifesciences Ltd.

ICICI Securities Limited

Astec Lifesciences Ltd. has lost -45.86% in the last 1 Year

Astec Lifesciences Ltd.

07 May 2019

667.10

-0.90%

Price hikes to support margin expansion in animal feed

Buy: Astec Lifesciences Ltd.

Motilal Oswal

Revenue grew 12.5% YoY to segment (+22% YoY to INR8.3b). EBITDA margin shrank 60bp YoY to 5.6% 7 May 2019 lower employee cost and other expenses. EBITDA was flat YoY at INR749m 13%/3%/11% YoY to INR58.7b/INR4.6b/INR2.4b. animal feed segment in 4QFY19 drove EBIT margin expansion of 250bp QoQ to 5.5%. GOAGRO is planning for two product launches in the standalone crop protection business. In Astec Lifesciences, it has guided for revenue and EBITDA growth of 15% and 20%, respectively, in FY20. We note that 4Q is a seasonally weak quarter for the palm oil business, wherein GOAGRO reported an EBIT loss of INR1m (v/s a profit of INR40m in 4QFY18) due to higher depreciation and interest cost for its new processing plant. (i) GOAGRO will revisit merger initiation with Astec Lifesciences after a few quarters.

Astec Lifesciences Ltd. has lost -29.01% in the last 3 Months

Is Astec Lifesciences Ltd. worth buying?

114 Votes:

Buy 80.7%

Sell 12.28%

Hold 7.02%